Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sandoz Group Ltd ( (CH:SDZ) ) has provided an announcement.
Sandoz has reached an agreement with Regeneron Pharmaceuticals to resolve all patent disputes related to its FDA-approved aflibercept biosimilar, Enzeevu™, clearing the way for its US launch by the end of 2026. This move is expected to bolster Sandoz’s position in the US ophthalmology market, expand its biosimilar portfolio, and enhance patient access to affordable medicines, thereby advancing its growth strategy and leadership in the industry.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF55.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. With a history dating back to 1886, Sandoz has been at the forefront of pharmaceutical innovation, including the development of the world’s first biosimilar. The company employs over 20,000 people worldwide and offers a portfolio of approximately 1,300 products, addressing a wide range of diseases and generating significant healthcare savings.
Average Trading Volume: 868,294
Technical Sentiment Signal: Buy
Current Market Cap: CHF21.51B
Learn more about SDZ stock on TipRanks’ Stock Analysis page.